CD274 and non-small cell lung carcinoma: As immunotherapies advance in the perioperative treatment of NSCLC, the IMpower010 trial, a randomized, multicenter, open-label phase III study, demonstrated that adjuvant atezolizumab treatment improved disease-free survival (DFS) compared to best supportive care (BSC) in patients with resected stage II–IIIA NSCLC with PD-L1 expression of 1% or more, as evaluated with Ventana SP263 (hazard ratio [HR] 0.66, 95% confidence interval [CI]: 0.50–0.88; p = 0.0039) [8].